Regeneron Pharmaceuticals, Inc. (REGN) Insider sold 15000 Shares

Lloyd Doyle
January 12, 2018

BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company's stock valued at $3,039,305,000 after buying an additional 41,406 shares during the period. Analysts are turning out to be more optimistic than before, with 12 of analysts who cover Regeneron Pharmaceuticals, Inc. At the close of regular trading, its last week's stock price volatility was 2.26% which for the month reaches 2.91%. About 347,274 shares traded.

Regeneron Pharmaceuticals (NASDAQ:REGN)'s stock had its "neutral" rating reiterated by analysts at Citigroup in a research note issued on Tuesday. It has outperformed by 0.70% the S&P500.

Stuyvesant Capital Management increased its stake in Mcewen Mng Inc (MUX) by 699.88% based on its latest 2017Q3 regulatory filing with the SEC.

The top 5 institutional holders, in ascending order, are as follows: FMR LLC with 6.99 million shares, CAPITAL WORLD INVESTORS with 6.57 million shares, BLACKROCK INC. with 6.13 million shares, VANGUARD GROUP INC with 5.4 million shares, and WELLINGTON MANAGEMENT GROUP LLP with 4.85 million shares. The company shares sank -1.84% from their peak of $405.05 and now has a $44.3 billion market value of equity. The stock decreased 0.72% or $2.66 during the last trading session, reaching $365.99. About 159,205 shares traded. (NYSE:BRO) has risen 19.69% since January 10, 2017 and is uptrending. It has outperformed by 7.04% the S&P500.

Since August 7, 2017, it had 2 insider purchases, and 8 insider sales for $78.43 million activity. Harding Loevner LP holds 1.98% of its portfolio in Regeneron Pharmaceuticals, Inc. Nisa Investment Advisors LLC now owns 15,440 shares of the biopharmaceutical company's stock valued at $6,207,000 after buying an additional 1,500 shares during the period. Fieldpoint Private Securities LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $130,000. It also increased its holding in Microsoft Corp (NASDAQ:MSFT) by 111,037 shares in the quarter, for a total of 792,779 shares, and has risen its stake in Lockheed Martin Corp (NYSE:LMT). TheStreet downgraded shares of Regeneron Pharmaceuticals from a b- rating to a c+ rating in a research report on Thursday, November 30th. Therefore 42% are positive. Pnc Fincl Gp reported 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 150 shares. The rating was maintained by UBS with "Buy" on Thursday, September 21. Credit Suisse maintained Regeneron Pharmaceuticals, Inc. The rating was initiated by Wells Fargo with "Outperform" on Friday, December 4. Guggenheim reiterated a "buy" rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. (NASDAQ:REGN) earned "Buy" rating by Chardan Capital Markets on Tuesday, August 4. (NASDAQ:REGN) on Thursday, September 7 with "Buy" rating. (NASDAQ:REGN). Colorado-based Icon Advisers has invested 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Monday, September 11. Morgan Stanley has 0% invested in Brown & Brown, Inc. (NASDAQ:REGN) was bought by Sanofi.

Investors sentiment decreased to 1.17 in Q3 2017. Revenue, on the other hand, scored -0.84% growth from the previous quarter, coming up with $1.46 billion. Tocqueville Asset Ltd Partnership has 499,241 shares for 0.57% of their portfolio. Parametric Port Associates Limited Liability Corporation has invested 0.08% in Regeneron Pharmaceuticals, Inc. Biondo Inv Advsrs Ltd Com reported 16,225 shares stake. (ISRG) price hitting a mean target of $386.88 a share, meaning the stock still has potential that could drag the price another -2.7% Also, the recent close suggests the stock is underpriced by 13.18% compared to the most bullish target.

MutualFirst Financial, Inc. operates as the bank holding firm for the MutualBank that provides various financial services to individuals, and small and mid-sized businesses in the United States. Chart Industries, Inc. (NASDAQ:GTLS) has risen 46.80% since January 12, 2017 and is uptrending. (NASDAQ:REGN). Natixis invested in 20,379 shares or 0.08% of the stock. Atlantic Limited Liability Corp accumulated 0.02% or 7,963 shares. Ing Groep Nv invested in 0.12% or 13,470 shares. Meiji Yasuda Asset Mngmt Limited holds 0.09% in Regeneron Pharmaceuticals, Inc. JPMorgan Chase & Co. reaffirmed a "hold" rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 31st. Of those holders, 294 had increased positions amounting to 3.98 million shares, 274 had decreased positions amounting to 4.15 million shares, and 96 holders have a held position accounting for 64.84 million shares.

Investors sentiment decreased to 1.16 in 2017 Q3. Its up 0.11, from 1.12 in 2017Q2. It fall, as 20 investors sold BRO shares while 79 reduced holdings. 43 funds opened positions while 164 raised stakes. Dimensional Fund Advsr Limited Partnership holds 1.10 million shares or 0.02% of its portfolio. 49,975 were reported by Moors & Cabot Inc. Following the completion of the transaction, the director now directly owns 36,500 shares of the company's stock, valued at approximately $15,670,910. 22,126 are held by Caisse De Depot Et Placement Du Quebec. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company's stock valued at $189,000 after purchasing an additional 96 shares during the last quarter. Balyasny Asset Mgmt Lc holds 0.14% or 750,722 shares in its portfolio. Cubist Systematic Strategies Ltd Liability Corp reported 13,293 shares. Hartford Mgmt reported 1.81% of its portfolio in The Walt Disney Company (NYSE:DIS).

Among 31 analysts covering Regeneron Pharmaceuticals Inc. REGN's profit will be $446.80M for 22.02 P/E if the $4.18 EPS becomes a reality. After $3.32 actual EPS reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 25.90% EPS growth. It also reduced its holding in Signature Bk New York N Y (NASDAQ:SBNY) by 8,210 shares in the quarter, leaving it with 749,134 shares, and cut its stake in Ctrip Com Intl Ltd (NASDAQ:CTRP).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article